Literature DB >> 22935578

Comparative evaluation of 18F-labeled glutamic acid and glutamine as tumor metabolic imaging agents.

Karl Ploessl1, Limin Wang, Brian P Lieberman, Wenchao Qu, Hank F Kung.   

Abstract

UNLABELLED: (18)F-labeled (2S,4R)-4-fluoro-l-glutamine (4F-GLN) has demonstrated high uptake in tumor cells that undergo high growth and proliferation. Similar tumor targeting properties have also been observed for (18)F-labeled (2S,4R)-4-fluoro-l-glutamate (4F-GLU), suggesting that both are useful imaging agents. A new labeling procedure facilitates the preparation of (18)F-(2S,4R)4F-GLN and (18)F-(2S,4R)4F-GLU with confirmed radiochemical and enantiomeric purity. Here, we report the preparation and comparative evaluation of (18)F-(2S,4R)4F-GLN and (18)F-(2S,4R)4F-GLU as tumor metabolic imaging agents.
METHODS: Uptake of enantiomerically pure (18)F-(2S,4R)4F-GLN and (18)F-(2S,4R)4F-GLU was determined in 3 tumor cell lines (9L, SF188, and PC-3) at selected time points. The in vitro cell uptake mechanism was evaluated by inhibition studies in 9L cells. In vivo biodistribution and PET studies were performed on male F344 rats bearing 9L tumor xenografts.
RESULTS: In vitro cell uptake studies showed that (18)F-(2S,4R)4F-GLN displayed higher uptake than (18)F-(2S,4R)4F-GLU. Amino acid transport system ASC (alanine-serine-cysteine-preferring; in particular, its subtype ASCT2 [SLC1A5 gene]) and system X(c)(-) (SLC7A11 gene) played an important role in transporting (18)F-(2S,4R)4F-GLN and (18)F-(2S,4R)4F-GLU, respectively, across the membrane. After being transported into cells, a large percentage of (18)F-(2S,4R)4F-GLN was incorporated into protein, whereas (18)F-(2S,4R)4F-GLU mainly remained as the free amino acid in its original form. In vivo studies of (18)F-(2S,4R)4F-GLN in the 9L tumor model showed a higher tumor uptake than (18)F-(2S,4R)4F-GLU, whereas (18)F-(2S,4R)4F-GLU had a slightly higher tumor-to-background ratio than (18)F-(2S,4R)4F-GLN. Imaging studies showed that both tracers had fast accumulation in 9L tumors. Compared with (18)F-(2S,4R)4F-GLU, (18)F-(2S,4R)4F-GLN exhibited prolonged tumor retention reflecting its incorporation into intracellular macromolecules.
CONCLUSION: Differences in uptake and metabolism in tumor cells were found between (18)F-(2S,4R)4F-GLN and (18)F-(2S,4R)4F-GLU. Both agents are potentially useful as metabolic tracers for tumor imaging.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22935578     DOI: 10.2967/jnumed.111.101279

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  42 in total

Review 1.  Glutamine and cancer: cell biology, physiology, and clinical opportunities.

Authors:  Christopher T Hensley; Ajla T Wasti; Ralph J DeBerardinis
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

2.  Glutaminolysis and carcinogenesis of oral squamous cell carcinoma.

Authors:  Marcel Cetindis; Thorsten Biegner; Adelheid Munz; Peter Teriete; Siegmar Reinert; Martin Grimm
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-02-07       Impact factor: 2.503

3.  Comparative enzymology of (2S,4R)4-fluoroglutamine and (2S,4R)4-fluoroglutamate.

Authors:  Arthur J L Cooper; Boris F Krasnikov; John T Pinto; Hank F Kung; Jianyong Li; Karl Ploessl
Journal:  Comp Biochem Physiol B Biochem Mol Biol       Date:  2012-05-19       Impact factor: 2.231

Review 4.  Radiopharmaceuticals as probes to characterize tumour tissue.

Authors:  Israt S Alam; Mubarik A Arshad; Quang-Dé Nguyen; Eric O Aboagye
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-03       Impact factor: 9.236

5.  Synthesis, Radiolabeling, and Biological Evaluation of (R)- and (S)-2-Amino-5-[(18)F]fluoro-2-methylpentanoic Acid ((R)-, (S)-[(18)F]FAMPe) as Potential Positron Emission Tomography Tracers for Brain Tumors.

Authors:  Ahlem Bouhlel; Dong Zhou; Aixiao Li; Liya Yuan; Keith M Rich; Jonathan McConathy
Journal:  J Med Chem       Date:  2015-05-04       Impact factor: 7.446

Review 6.  Cancer cell metabolism: the essential role of the nonessential amino acid, glutamine.

Authors:  Ji Zhang; Natalya N Pavlova; Craig B Thompson
Journal:  EMBO J       Date:  2017-04-18       Impact factor: 11.598

Review 7.  From Krebs to clinic: glutamine metabolism to cancer therapy.

Authors:  Brian J Altman; Zachary E Stine; Chi V Dang
Journal:  Nat Rev Cancer       Date:  2016-07-29       Impact factor: 60.716

Review 8.  (11)C[double bond, length as m-dash]O bonds made easily for positron emission tomography radiopharmaceuticals.

Authors:  Benjamin H Rotstein; Steven H Liang; Michael S Placzek; Jacob M Hooker; Antony D Gee; Frédéric Dollé; Alan A Wilson; Neil Vasdev
Journal:  Chem Soc Rev       Date:  2016-08-22       Impact factor: 54.564

9.  Glutamate-Weighted Chemical Exchange Saturation Transfer Magnetic Resonance Imaging Detects Glutaminase Inhibition in a Mouse Model of Triple-Negative Breast Cancer.

Authors:  Rong Zhou; Puneet Bagga; Kavindra Nath; Hari Hariharan; David A Mankoff; Ravinder Reddy
Journal:  Cancer Res       Date:  2018-08-02       Impact factor: 12.701

10.  Functional imaging of oxidative stress with a novel PET imaging agent, 18F-5-fluoro-L-aminosuberic acid.

Authors:  Jack M Webster; Christine A Morton; Bruce F Johnson; Hua Yang; Michael J Rishel; Brian D Lee; Qing Miao; Chittari Pabba; Donald T Yapp; Paul Schaffer
Journal:  J Nucl Med       Date:  2014-02-27       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.